Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 10, 2006, Pages 3941-3946

  Eng Wong, Jennifer ^a,b   Reynolds, J C ^b   Venzon, D ^b   Liewehr, D ^b   Gantz, S ^b   Danforth, D ^a   Liu, E T ^c   Chow, C ^b   Zujewski, J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FIBRINOGEN; LIPID; RALOXIFENE;

ADULT; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HEADACHE; HIGH RISK POPULATION; HIP; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LEG CRAMP; LUMBAR SPINE; MASTALGIA; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; MYALGIA; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; UNIVERSITY HOSPITAL; VAGINA DISCHARGE;

EID: 33749573615     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2827     Document Type: Article

References (33)

1. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon Jr ER, Wade 3rd JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
3. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 65:125-134
4. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, Cohen F, Watts S, Netelenbos C 1999 Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19:2993-3000
5. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ 1994 Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86:1534-1539
6. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK 2000 A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95:95-103
7. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S 1996 Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84
8. Eng-Wong J, Hursting SD, Venzon D, Perkins SN, Zujewski JA 2003 Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev 12:1468-1473
9. Faupel-Badger JM, Prindiville SA, Venzon D, Vonderhaar BK, Zujewski JA, Eng-Wong J 2006 Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev 15:1153-1158
10. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ 1989 Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886
11. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Thomas A, et al 1997 BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278:1242-1250
12. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services 1998 Common toxicity criteria, version 2.0. Bethesda, MD: National Cancer Institute
13. Ware JE, Kosinski MA, Gandek B 2002 In: SF-36 health survey manual and interpretation guide. Lincoln, RI: QualityMetric Inc.
14. Barkhem T, Andersson-Ross C, Hoglund M, Nilsson S 1997 Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes. J Steroid Biochem Mol Biol 62:53-64
15. Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S 2002 The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30:368-376
16. Sibonga JD, Evans GL, Hauck ER, Bell NH, Turner RT 1996 Ovarian status influences the skeletal effects of tamoxifen in adult rats. Breast Cancer Res Treat 41:71-79
17. Braidman IP, Hainey L, Batra G, Selby PL, Saunders PT, Hoyland JA 2001 Localization of estrogen receptor beta protein expression in adult human bone. J Bone Miner Res 16:214-220
18. Bonnelye E, Aubin JE 2005 Review: estrogen receptor-related receptor α: a mediator of estrogen response in bone. J Clin Endocrinol Metab 90:3115-3121
19. Makita K, Ishitani K, Ohta H, Horiguchi F, Nozawa S 2005 Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate. J Bone Miner Metab 23:389-394
20. Amama EA, Taga M, Minaguchi H 1998 The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover. J Clin Endocrinol Metab 83:333-338
21. Morgante G, La Marca A, Ditto A, Musacchio MC, Cavicchioli C, Lanzetta D, Petraglia F, De Leo V 2001 Comparison of biochemical markers of bone turnover and bone mineral density in different groups of climacteric women. Gynecol Endocrinol 15:466-471
22. Seifert-Klauss V, Mueller JE, Luppa P, Probst R, Wilker J, Hoss C, Treumann T, Kastner C, Ulm K 2002 Bone metabolism during the perimenopausal transition: a prospective study. Maturitas 41:23-33
23. Johnston Jr CC, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath 3rd H, Gennari C, Christiansen C, Arnaud CD, Delmas PD 2000 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444-3450
24. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW 2000 The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85:214-218
25. Mosca L 2001 Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann NY Acad Sci 949:181-185
26. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M 2001 Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 93:16-21
27. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197
28. Cohen FJ, Lu Y 2000 Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 34:65-73
29. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B 1999 Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659-2669
30. Recker RR, Lappe JM, Davies KM, Kimmel DB 1992 Change in bone mass immediately before menopause. J Bone Miner Res 7:857-862
31. Sowers MR, Clark MK, Hollis B, Wallace RB, Jannausch M 1992 Radial bone mineral density in pre- and perimenopausal women: a prospective study of rates and risk factors for loss. J Bone Miner Res 7:647-657
32. Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S 2005 Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 103:1996-2005
33. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM 2004 Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22:4951-4957